TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03500705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Education of Strengthening.
Description: Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Education of Strengthening.
Description: Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
Study: NCT02842879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Foley cervix priming
Description: Outpatient setting for cervix priming with Foley catheter
Study: NCT05018962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutting balloon followed by paclitaxel coated balloon
Description: Cutting balloon followed by paclitaxel coated balloon
Study: NCT02554175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol was administered to achieve target propofol Ce
Study: NCT00394511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT03579875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 35 mg/m2 IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 35 mg/m2 IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 35 mg/m2 IV daily on days -5, -4, -3, and -2
Study: NCT03725943

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dreem
Description: Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
Study: NCT05767138

Intervention type: BEHAVIORAL
Intervention: HPV Vaccine Acceptance Survey
Study: NCT02225275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT03643588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan
Description: Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
Study: NCT04310774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)
Description: CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
Study: NCT04273685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training, social recovery therapy
Description: 10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: 10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
Study: NCT00070629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6
Study: NCT00725582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA-026

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00712855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mapatumumab
Description: 3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg orally, twice a day continuously in each cycle
Study: NCT03082209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-621
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: IV infusion
Study: NCT02815254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity functional exercise
Study: NCT00738530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: 10 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a [Roferon]
Description: 9 MIU SC 3 times/week
Study: NCT02815254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity functional exercise
Study: NCT03579875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 35 mg/m2 IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 35 mg/m2 IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Description: 1 mg/kg IV q12h on days -5, -4, -3, -2, and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Description: 1 mg/kg IV q12h on days -5, -4, -3, -2, and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Description: 1 mg/kg IV q12h on days -5, -4, -3, -2, and -1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Donor mobilized PBSC infusion
Description: T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Donor mobilized PBSC infusion
Description: T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days)
Study: NCT00738530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon alfa 2a [Roferon]
Description: 9 MIU SC 3 times/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV every 2 weeks
Study: NCT04101864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation
Description: Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand
Description: In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
Study: NCT01223859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial soft palate surgery
Description: Soft palate RF surgery in local anaesthesia
Study: NCT00669695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin treatment
Description: Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin treatment
Description: Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
Study: NCT00908011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin (standard care)
Description: Increased dose of rosuvastatin to 20mg/day
Study: NCT03718039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.
Study: NCT03579875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days)
Study: NCT00669695

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CPAP device
Description: This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
Study: NCT01190371

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate
Description: Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
Study: NCT00669695

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CPAP device
Description: This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
Study: NCT03718039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Aprepitant, three single doses of aprepitant will be administered orally.
Study: NCT02052817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy Debridement + Toad Brace

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy - Debridement
Study: NCT03579875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (Plan 2)
Description: 5 mg/kg IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 IV once on day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 IV once on day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 IV once on day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
Study: NCT02467452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FlF/VI + Tiotropium
Study: NCT02288728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric tube anastomosis
Description: In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-track anastomosis
Description: Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)
Study: NCT00669695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham CPAP treatment
Description: This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham CPAP treatment
Description: This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
Study: NCT00811889

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01744847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide
Description: one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
Study: NCT00811889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl (RTA 402)
Description: Oral, Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl (RTA 402)
Description: Oral, Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl (RTA 402)
Description: Oral, Once Daily
Study: NCT01013220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Product Detailing
Description: 1. two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~2. technical assistance in purchasing high quality depression management products

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Depression HEDIS detailing
Description: 1. academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~2. technical assistance
Study: NCT01693146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen insufflation with a TNI® 20 oxy device
Description: Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal insufflation of oxygen
Description: Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
Study: NCT00768599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate Cream 1%
Description: Topical cream, applied once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Foam 1%
Description: Topical foam, applied once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical foam, applied once daily for 4 weeks.
Study: NCT02173353

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound to be done just before standard radiation therapy treatment
Study: NCT03835117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wide-spectrum nutritional supplement
Description: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo comparator
Study: NCT00801242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg / 80 mg
Description: For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
Study: NCT02053311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orteronel
Description: 300mg orteronel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02817503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard BP control
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate BP control
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive BP control
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
Study: NCT02420275

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: THIS GROUP WILL RECEIVE NO BRIGHT LIGHT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminette,Lucimed Belgium
Description: THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
Study: NCT01166087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study: NCT04142125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet bid
Description: Pts will receive rivaroxaban + aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicyclic acid 81 mg tablet qd
Description: Pts will receive ASA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid 81 mg tablet qd
Description: Pts will receive ASA
Study: NCT01873677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01863966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot water drinking therapy
Description: Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic dilation
Description: Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
Study: NCT03112278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic ultrathin occlusal veneers
Description: Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Composite resin ultrathin occlusal veneers
Description: Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
Study: NCT02217995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams \& Teasdale, 2002).
Study: NCT00705640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously and intradermally
Study: NCT01783626

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Evodial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial+ Condition B1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial+ Condition B2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial+ Condition C